A Randomized, Controlled, Multicenter Phase 4 Clinic Trial to Evaluate the Immunogenicity and Safety of Combined Immunization of Sabin-strain Inactivated Polio Vaccine (sIPV), Diphtheria, Tetanus, Pertussis Vaccine (DTaP) and Measles, Moms and Rubella Vaccine (MMR)
Latest Information Update: 06 Dec 2022
Price :
$35 *
At a glance
- Drugs DTaP poliovirus vaccine (Primary) ; Measles mumps and rubella virus vaccine (Primary) ; Poliovirus vaccine inactivated Intravacc/Sinovac/WHO (Primary)
- Indications Diphtheria; Measles; Mumps; Pertussis; Poliomyelitis; Rubella; Tetanus
- Focus Pharmacodynamics
- Sponsors China National Biotec Group
- 09 Dec 2020 Status changed from not yet recruiting to recruiting.
- 27 Nov 2020 New trial record